Related Experiment Video
Updated: Sep 1, 2026

Gene-environment Interaction Models to Unmask Susceptibility Mechanisms in Parkinson's Disease
Published on: January 7, 2014
Brain monoamine oxidase (MAO) B: a unique neurotoxin and neurotransmitter producing enzyme
1Rappaport Family Research Institute, Technion Faculty of Medicine, Department of Pharmacology, Haifa, Israel.
Abstract:
The notion that monoamine oxidase (MAO) functions solely to inactivate neurotransmitter and other biogenic amines needs to be re-evaluated. It is now apparent that MAO-B is capable of oxidizing inert non-polar amines such as MPTP (N-methyl-4-phenyl-1,2,3,6, tetrahydropyridine) and milacemide (2-n-pentylaminoacetamide) into neuroactive substances giving rise to Parkinson inducing dopaminergic neurotoxin, MPP+ and inhibitory amino acid neurotransmitter, glycine respectively. These findings accord new prospectives for neuropsychotherapy with selective MAO-B inhibitors and substrates.
Insights
Monoamine oxidase-B (MAO-B) can activate inert amines into neuroactive substances. This challenges the view of MAO-B as only inactivating neurotransmitters and offers new therapeutic strategies.
Area of Science:
- Neuroscience
- Biochemistry
- Pharmacology
Background:
- Monoamine oxidase (MAO) traditionally viewed as solely inactivating neurotransmitters.
- Emerging evidence suggests MAO-B has broader substrate capabilities.
Purpose of the Study:
- To re-evaluate the functional role of MAO-B beyond neurotransmitter inactivation.
- To investigate MAO-B's capacity to oxidize non-polar amines into neuroactive compounds.
Main Methods:
- Enzymatic assays using MAO-B.
- Oxidation of specific inert non-polar amine substrates, including MPTP and milacemide.
- Analysis of reaction products for neuroactivity.
Main Results:
- MAO-B oxidizes N-methyl-4-phenyl-1,2,3,6, tetrahydropyridine (MPTP) to MPP+, a Parkinsonism-inducing dopaminergic neurotoxin.
- MAO-B also oxidizes milacemide to glycine, an inhibitory amino acid neurotransmitter.
- Demonstrates MAO-B's capability to generate both neurotoxic and neuroactive substances from inert precursors.
Conclusions:
- The function of MAO-B is not limited to neurotransmitter inactivation.
- MAO-B plays a critical role in the bioactivation of certain xenobiotics and endogenous compounds.
- Selective MAO-B inhibitors and substrates present novel therapeutic avenues for neuropsychiatric disorders.
Related Concept Videos
Neurochemical Transmission: Sites of Drug Action
Adrenergic Neurons: Neurotransmission
Synthesis: Catecholamine synthesis requires tyrosine, which is taken...
Adrenergic Agonists: Indirect-Acting Agents
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral bioavailability, and...
Drugs Affecting Neurotransmitter Release or Uptake
Drugs Affecting Neurotransmitter Synthesis
Antidepressant Drugs: MAOIs and Other Agents

